암 치료용 유전체학 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global genomics in cancer care market size is expected to reach USD 112.87 Billion in 2034 from USD 28.42 Billion in 2025, growing at a CAGR of 16.56% during 2026-2034.This market is expanding as genomics becomes increasingly important in understanding cancer development, identifying genetic alterations, and guiding treatment decisions. Genomic testing enables healthcare professionals to examine tumor characteristics and identify molecular changes that may influence disease progression. Growing demand for precision oncology, improvements in sequencing technologies, and increasing awareness of personalized cancer treatment are supporting adoption. Healthcare institutions are incorporating genomic information into diagnostic and treatment workflows to improve clinical decision-making. These developments are strengthening the role of genomic analysis in cancer detection, treatment selection, and disease monitoring.

Market growth is driven by advancements in next-generation sequencing, declining sequencing costs, and increasing investments in cancer research. Pharmaceutical companies are using genomic data to identify potential drug targets and support the development of targeted therapies. Meanwhile, hospitals, diagnostic laboratories, and research institutions are expanding their capabilities to perform molecular profiling. Growing collaborations between biotechnology companies and healthcare providers are also supporting innovation. The integration of artificial intelligence and bioinformatics tools is improving the interpretation of complex genomic datasets, helping researchers identify clinically relevant mutations and investigate new treatment opportunities.

The future of this market is expected to be influenced by broader access to genomic testing, improved data analysis, and the continued development of targeted cancer therapies. Advances in liquid biopsy and comprehensive genomic profiling may support less invasive testing and more frequent disease monitoring. Greater integration of genomic information into clinical guidelines could further strengthen its role in routine oncology care. However, challenges related to reimbursement, data privacy, testing costs, and unequal access to specialized services will remain important considerations. Addressing these barriers could help expand the application of genomics across different cancer types and healthcare settings.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Instruments
• Consumables
• Services

By Application

• Diagnostics
• Personalized Medicine
• Drug Discovery & Development
• Research

By Technology

• Genome Sequencing
• PCR
• Microarrays
• Nucleic Acid Extraction and Purification
• Other

COMPANIES PROFILED

• Illumina, Thermo Fisher Scientific, Foundation Medicine, Guardant Health, Natera, Tempus AI, Exact Sciences, Caris Life Sciences, Invitae, NeoGenomics, QIAGEN, Roche, Agilent Technologies, Bio-Rad Laboratories, F. Hoffmann-La Roche, Personalis, Burning Rock Biotech, BGI Genomics, GeneCentric Therapeutics, GRAIL

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENOMICS IN CANCER CARE MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENOMICS IN CANCER CARE MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Research Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENOMICS IN CANCER CARE MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Technology
• 6.2. Genome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Microarrays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Nucleic Acid Extraction and Purification Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENOMICS IN CANCER CARE MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Application
  • 7.2.3 By Technology
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Application
  • 7.3.3 By Technology
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Application
  • 7.4.3 By Technology
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Application
  • 7.5.3 By Technology
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Application
  • 7.6.3 By Technology
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GENOMICS IN CANCER CARE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Illumina
  • 9.2.2 Thermo Fisher Scientific
  • 9.2.3 Foundation Medicine
  • 9.2.4 Guardant Health
  • 9.2.5 Natera
  • 9.2.6 Tempus AI
  • 9.2.7 Exact Sciences
  • 9.2.8 Caris Life Sciences
  • 9.2.9 Invitae
  • 9.2.10 NeoGenomics
  • 9.2.11 QIAGEN
  • 9.2.12 Roche
  • 9.2.13 Agilent Technologies
  • 9.2.14 Bio-Rad Laboratories
  • 9.2.15 F. Hoffmann-La Roche
  • 9.2.16 Personalis
  • 9.2.17 Burning Rock Biotech
  • 9.2.18 BGI Genomics
  • 9.2.19 GeneCentric Therapeutics
  • 9.2.20 GRAIL